Table 2.

Subgroup Analysis of the RCTs Meta-Analyses (see Figure 2).

Moderator	N studies	HR	95% CI		Heterogeneity I2 (%)	z-score	P-value
Cancer type
Colorectal cancer	3	0.81	0.62	1.05	0	1.59	.11
Other	7	0.81	0.66	1	0	1.96	.05
Product type
Helixor	5	0.7	0.6	0.83	7	4.29	<.0001
Eurixor	3	0.78	0.54	1.12	0	1.34	.18
Type of survival
OS	4	0.8	0.63	1.03	0	1.73	.08
Other	6	0.78	0.62	0.97	22	2.24	.02
Tumor stage
1-3	5	0.82	0.65	1.03	0	1.7	.09
Including stage 4	6	0.82	0.64	1.06	0	1.53	.13
Risk of bias
High risk	2	0.91	0.59	1.4	0	0.42	.68
Some concern	8	0.79	0.67	0.95	0	2.56	.01